Fore Biotherapeutics
Israel - RehovotBiotechnology
Focus: Fore Biotherapeutics is an Israel-based oncology-focused biotech company developing BRAF inhibitors and partnering through in-licensing strategies. The company is in Series C+ stage with early-stage pipeline programs across Phase 1-2 development.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Funding Stage
SERIES C +
Open Jobs
2
Should You Work at Fore Biotherapeutics?
AI assessmentFore Biotherapeutics suits early-career scientists or specialists willing to bet on early oncology programs, but limited hiring and sparse transparency create uncertainty around long-term career advancement.
Why Work Here
- Focused oncology portfolio with multiple BRAF-targeted programs addressing significant cancer indications with known market demand
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
8 total
LOE Risk
Protected
No near-term cliffs
Hiring
2 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
NovellusDx Functional Profiling of Oncogenic Mutations in Lung Cancer Patients
Lung CancerNovellusDx Tissue Collection Protocol
Patients That Have Been Diagnosed With Colorectal CancerHelp build intelligence for Fore Biotherapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.